|Bid||8.40 x 1000|
|Ask||8.72 x 800|
|Day's range||8.38 - 9.91|
|52-week range||7.08 - 40.91|
|Beta (5Y monthly)||2.07|
|PE ratio (TTM)||N/A|
|Earnings date||28 Dec 2021 - 03 Jan 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||28 Aug 1996|
|1y target est||12.00|
VIENNA, Va., October 22, 2021--CEL-SCI Corporation completes commercial-scale buildout of Multikine manufacturing facility.
VIENNA, Va., August 16, 2021--CEL-SCI Corporation reports third quarter fiscal 2021 financial results.
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE: CVM). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 7980. The investigation concerns whether CEL-SCI and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]